Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
SHPL primarily manufactures, sells, and distributes its own-brand prescription medicines in China, predominantly for cardiovascular diseases.On Wednesday, Hutchmed (China) Limited (NASDAQ:HCM) entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million (RMB 4.478 billion) in cash to GP Health Service Capital Co., Ltd and Shanghai Pharmaceuticals Holding Co., Ltd.
在週三，和黃醫藥（中國）有限公司（納斯達克:HCM）簽署了兩項協議，將其在上海和黃藥業有限公司（SHPL）持有的45%股權以大約60800萬美金（人民幣44.78億）現金出售給GP Health Service Capital Co., Ltd 和上海醫藥控股有限公司。
Hutchmed has been exploring opportunities to monetize the underlying value of SHPL, a non-core, non-consolidated joint venture.
和黃醫藥一直在探索變現SHPL這一非核心、非合併合資企業的潛在價值的機會。
These transactions would allow Hutchmed to focus on its core business of discovering, developing, and commercializing novel therapies for cancers and immunological diseases, including advancing its next-generation antibody-targeted therapy conjugate programs.
這些交易將使和黃醫藥能夠專注於其核心業務，發現、開發和商業化創新的癌症和免疫疾病療法，包括推進其下一代抗體靶向治療聯合體項目。
SHPL primarily manufactures, sells, and distributes its own-brand prescription medicines in China, predominantly for cardiovascular diseases.
SHPL主要在中國製造、銷售和分銷自有品牌的處方藥，主要用於心血管疾病。
SHPL is a 50:50 joint venture established between Hutchmed and Shanghai Pharma in 2001.
SHPL是和黃醫藥與上海醫藥於2001年成立的一個50:50合資企業。
In 2023, the consolidated net income attributable to Hutchmed from SHPL was $47.4 million. HUTCHMED does not consolidate revenue from SHPL.
在2023年，歸屬於和黃醫藥的SHPL合併凈利潤爲4740萬美元。和黃醫藥不合並來自SHPL的營業收入。
Hutchmed plans to invest the proceeds from these transactions to further develop its internal pipeline and advance its core business strategy.
和黃醫藥計劃將這些交易的收益投資於進一步開發其內部管線，並推進其核心業務策略。
Hutchmed plans to move the first of these antibody-targeted therapy conjugates into clinical trials in the second half of 2025.
和黃醫藥計劃在2025年下半年將首個抗體靶向治療聯合體推進到臨牀試驗中。
Before the transactions, Hutchmed and Shanghai Pharma each hold a 50% equity interest in SHPL. GP Health Service Capital has agreed to acquire a 35% equity interest for approximately $473 million in cash, and Shanghai Pharma will acquire a 10% equity interest for approximately $135 million in cash.
在交易之前，和黃醫藥和上海醫藥各持有SHPL 50%的股權。GP Health Service Capital已同意以約47300萬美元的現金收購35%的股權，而上海醫藥將以約13500萬美元的現金收購10%的股權。
After the transactions, the investors will hold a 60% equity interest in SHPL. Out of its 35%, GP Health Service Capital retains the right to designate a third-party investment fund to acquire up to a 10% equity interest in SHPL.
完成交易後，投資者將持有SHPL 60%的股權。在其35%的股權中，GP Health Service Capital保留指定第三方投資基金收購SHPL最多10%股權的權利。
Hutchmed will retain a 5% equity interest in SHPL after the transactions.
交易完成後，和黃醫藥將保留SHPL 5%的股權。
Hutchmed expects to record a gain on disposal of approximately $477 million before taxation.
和黃醫藥預計在稅前錄得約47700萬美元的處置收益。
On Wednesday, Hutchmed announced that the China National Medical Products Administration accepted and granted priority review of the New Drug Application for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) for locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET amplification after disease progression.
週三，和黃醫藥宣佈中國國家醫療產品管理局接受並優先審查組合藥物Orpathys（savolitinib）和Tagrisso（osimertinib）提交的新藥申請，用於處理局部晚期或轉移性表皮生長因數受體突變陽性非小細胞肺癌且伴有MET擴增的患者。
The acceptance also triggers a milestone payment from AstraZeneca plc (NASDAQ:AZN).
此批准還觸發了阿斯利康（納斯達克：AZN）的里程碑付款。
Price Action: At last check on Wednesday, HCM stock was up 7.98% at $15.56 during the premarket session.
價格動態：週三最後檢查時，HCm股票在盤前交易中上漲了7.98%，報15.56美元。
- Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?
- 爲什麼專注於腦癌的Kazia Therapeutics股票在週二交易下跌？
